108 related articles for article (PubMed ID: 30537918)
1. Dose-related periorbital edema following sorafenib in a patient with acute myeloid leukemia.
Freyer CW; Mangan JK
J Oncol Pharm Pract; 2019 Dec; 25(8):2035-2037. PubMed ID: 30537918
[TBL] [Abstract][Full Text] [Related]
2. [Sorafenib - induced thyroiditis in patient with a relapse of acute myelomonocytic leukemia with FLT3-ITD mutation].
Balzhanova YB; Parovichnikova EN; Sokolov AN; Ryzhko VV; Samtsova MA; Gribanova EO
Ter Arkh; 2019 Aug; 91(8):93-97. PubMed ID: 32598759
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/ Refractory Acute Myeloid Leukemia.
Yang N; Gu Z; Liu Z; Huang W; Wang S; Wang L; Gao C
Anticancer Agents Med Chem; 2018; 18(10):1489-1494. PubMed ID: 29521250
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship.
Liu T; Ivaturi V; Sabato P; Gobburu JVS; Greer JM; Wright JJ; Smith BD; Pratz KW; Rudek MA;
Clin Transl Sci; 2018 Jul; 11(4):435-443. PubMed ID: 29702736
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
Battipaglia G; Ruggeri A; Massoud R; El Cheikh J; Jestin M; Antar A; Ahmed SO; Rasheed W; Shaheen M; Belhocine R; Brissot E; Dulery R; Eder S; Giannotti F; Isnard F; Lapusan S; Rubio MT; Vekhoff A; Aljurf M; Legrand O; Mohty M; Bazarbachi A
Cancer; 2017 Aug; 123(15):2867-2874. PubMed ID: 28387928
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib improves survival of
Bazarbachi A; Labopin M; Battipaglia G; Djabali A; Passweg J; Socié G; Forcade E; Blaise D; Chevallier P; Orvain C; Cornelissen JJ; Arcese W; Chantepie S; Hashaishi K; El Cheikh J; Medinger M; Esteve J; Nagler A; Mohty M
Haematologica; 2019 Sep; 104(9):e398-e401. PubMed ID: 30792203
[No Abstract] [Full Text] [Related]
7. Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia.
Kakiuchi S; Yakushijin K; Sakai R; Kawaguchi K; Higashime A; Kurata K; Ichikawa H; Nagao S; Rikitake J; Kiyota N; Matsuoka H; Minami H
J Oncol Pharm Pract; 2019 Dec; 25(8):2010-2015. PubMed ID: 30514174
[TBL] [Abstract][Full Text] [Related]
8. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
9. Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
Fathi AT; Lin WM; Durazzo T; Piris A; Sadrzadeh H; Bernardo L; Borger DR; McAfee SL; Kroshinsky D; Chen YB
J Clin Oncol; 2016 Mar; 34(8):e70-2. PubMed ID: 25024084
[No Abstract] [Full Text] [Related]
10. Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
Giri S; Hamdeh S; Bhatt VR; Schwarz JK
J Natl Compr Canc Netw; 2015 May; 13(5):508-14. PubMed ID: 25964636
[TBL] [Abstract][Full Text] [Related]
11. Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.
Lee SH; Paietta E; Racevskis J; Wiernik PH
Am J Hematol; 2009 Oct; 84(10):701-2. PubMed ID: 19714594
[No Abstract] [Full Text] [Related]
12. Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy.
Schroeder T; Zohren F; Saure C; Bruns I; Czibere A; Safaian NN; Fenk R; Haas R; Kobbe G
Acta Haematol; 2010; 124(3):153-9. PubMed ID: 20938170
[No Abstract] [Full Text] [Related]
13. Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia.
Mohan BP; How GF; Loh Y; Linn YC
Br J Haematol; 2012 Apr; 157(1):131-2. PubMed ID: 22050655
[No Abstract] [Full Text] [Related]
14. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in
Zhang W; Ly C; Ishizawa J; Mu H; Ruvolo V; Shacham S; Daver N; Andreeff M
Haematologica; 2018 Oct; 103(10):1642-1653. PubMed ID: 29773601
[TBL] [Abstract][Full Text] [Related]
15. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
[TBL] [Abstract][Full Text] [Related]
16. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
Lierman E; Lahortiga I; Van Miegroet H; Mentens N; Marynen P; Cools J
Haematologica; 2007 Jan; 92(1):27-34. PubMed ID: 17229632
[TBL] [Abstract][Full Text] [Related]
17. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib Therapy for Pediatric Acute Myeloid Leukemia with FMS-like Tyrosine Kinase 3-internal Tandem Duplication Mutations: 2 Case Reports.
Osone S; Imamura T; Kanayama T; Tsuma Y; Kawashima-Goto S; Nakatani T; Sugimoto A; Takai A; Miyachi M; Tamura S; Ishida H; Hosoi H
J Pediatr Hematol Oncol; 2017 May; 39(4):e199-e202. PubMed ID: 27571118
[TBL] [Abstract][Full Text] [Related]
19. FLT3 inhibitors for the treatment of acute myeloid leukemia.
Wiernik PH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib-induced Posterior Reversible Encephalopathy Syndrome in a Child With FLT3-ITD-positive Acute Myeloid Leukemia.
Tavil B; Isgandarova F; Bayhan T; Unal S; Kuskonmaz B; Gumruk F; Cetin M
J Pediatr Hematol Oncol; 2016 Apr; 38(3):240-2. PubMed ID: 26907662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
